(Solid Tumors) Is Pralsetinib Effective? ARROW Phase 1/2 Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- September 12, 2022
- 1 min read
On August 12, 2022, Vivek Subbiah and colleagues from The University of Texas MD Anderson Cancer Center published results in Nature Medicine from the ARROW Phase 1/2 clinical trial evaluating the efficacy and safety of pralsetinib monotherapy in patients with RET fusion-positive advanced solid tumors.
Trial Design:
The ARROW Phase 1/2 trial enrolled previously treated patients with RET fusion-positive advanced solid tumors ineligible for standard treatment (N=29) who received pralsetinib monotherapy. The primary endpoint was objective response rate (ORR).
Results (N=23 evaluable):
- ORR: 57%
- Complete response (CR): 13%
- Partial response (PR): 43%
- Median duration of response: 11.7 months
- Median PFS: 7 months
- Median OS: 14 months
- Grade 3+ adverse events: neutropenia 31%, anemia 14%
Conclusion: Based on the ARROW Phase 1/2 trial results, Vivek Subbiah and colleagues concluded that pralsetinib monotherapy demonstrated rapid, potent, and durable anti-tumor activity with acceptable tolerability in patients with RET fusion-positive advanced solid tumors.
Source: https://www.nature.com/articles/s41591-022-01931-y
Solid Tumors | RET Fusion | Pralsetinib | ARROW Trial
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4